+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies

Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies

Journal of Laboratory and Clinical Medicine 100(6): 986-996

Dilute clot lysis was assayed by release of soluble 125I fibrin degradation products from dPPP [dilute platelet-poor plasma] clots containing varying amounts of plasminogen activator and platelets. Plasminogen activator in the absence of platelets gave an approximately linear rate of lysis, with a rate proportional to its concentration. Addition of platelets to achieve normal clot retraction had little effect on the lysis rate in the absence of plasminogen activator or in the presence of very high plasminogen activator levels. With intermediate plasminogen activator levels, platelet-mediated clot retraction was associated with an accelerated rate of clot lysis when retraction reached 75-90%. The length of the lag phase before the start of the accelerated phase varied with the number of platelets and rate of clot retraction. The interaction of clot retraction and lysis was further explored in selected patients to determine whether the contributions of platelet and plasma factors in these cases were similar to those seen in studies of reconstituted plasma and whether the experience with reconstituted systems could be used in the study of disorders of fibrinolysis involving platelets and fibrinolytic enzymes.

(PDF emailed within 1 workday: $29.90)

Accession: 006133018

Download citation: RISBibTeXText

PMID: 6890569

Related references

Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator. Thrombosis and Haemostasis 61(3): 502-506, 1989

Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thrombosis and Haemostasis 63(1): 82-86, 1990

Attenuation of clot lysis in plasminogen activator inhibitor type-1 released from platelets. Circulation 86(4 SUPPL 1): I176, 1992

Influence of kringles k 1 3 k 4 and k 5 on tissue plasminogen activator induced fibrin clot lysis in the presence of glutamic acid and lysine plasminogen. Ukrainskii Biokhimicheskii Zhurnal 61(4): 31-36, 1989

Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thrombosis and Haemostasis 57(3): 372-373, 1987

Prophylaxis with tissue type plasminogen activator accelerated clot lysis by tissue type plasminogen activator present before clot formation. American Heart Association Monograph (107): II-27, 1984

Influence of the plasma concentration of plasminogen activator inhibitor, plasminogen, fibrinogen and streptokinase antibodies on results of an activated microtitre clot lysis assay. Fibrinolysis 8(SUPPL 1): 127, 1994

Effect of pentosan polysulfate on activated partial thromboplastin time, thrombin time, euglobulin clot lysis, and on tissue-type plasminogen activator and plasminogen activator inhibitor activities in patients with thromboembolic disease. Seminars in Thrombosis and Hemostasis 17(4): 394-398, 1991

Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Thrombosis and Haemostasis 56(1): 35-39, 1986

Absence of synergism between tissue type plasminogen activator single chain urokinase type plasminogen activator and urokinase on clot lysis in a plasma milieu in vitro. Thrombosis & Haemostasis 56(1): 35-39, 1986

Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs. Neurosurgery 40(3): 572-577, 1997

Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Thrombosis and Haemostasis 91(3): 473-479, 2004

Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 79(6): 1420-1427, 1992

Platelet induced clot retraction inhibits streptokinase sk but not tissue plasminogen activator t pa mediated clot lysis. Circulation 82(4 SUPPL 3): III375, 1990